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One major challenge in gene therapy is the host immune responses against viral vectors. Previous studies indicate the
involvement of NK cells in stunted gene expression in viral vector mediated gene therapy. To understand the problem of
the immune responses, we have developed an in-vitro co-culture system with human NK cell line, macrophages and
airway epithelial cells. We showed that small molecule blockers, CAPE and ruxolitinib, for NF-κB and JAK-STAT pathways,
respectively, significantly inhibited cytokine secretion by macrophages. When NK cells are co-cultured with helper-
dependent adenoviral (HD-Ad) vector activated macrophages, IFN-γ cytokine expression by NK cells increased significantly,
which was inhibited effectively by ruxolitinib and CAPE, and there was an additive effect when both inhibitors were used.
We demonstrated that NK cells activated by cytokines produced by HD-Ad-activated macrophages kill HD-Ad vector
transduced bronchial epithelial cells. This cell killing activity was significantly reduced by CAPE and ruxolitinib.
Combination of these two inhibitors had an additive effect on inhibiting NK cell mediate killing of gene transduced cells.
Transient inhibition of NK cell response at its peak may enhance sustained gene expression. Our data suggest that
combination of CAPE and ruxolitinib may help in protecting gene transduced airway epithelial cells to prolong transgene
expression.
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Our ability to detect genetic deletions and mutations that
cause human diseases has immensely improved due to
tremendous progress in human genetics [1, 2]. However,
the current major hurdle to realize the full potential of
therapeutic benefits from advancements in genetics is the
slow progress in translating our knowledge into clinical
therapeutic applications. Conceptually, correction of a
genetic mutation/deletion that causes a disease should
allow us to treat/cure the disease at its cause, not its
symptoms, thereby, revolutionizing the human medicine.
But, technically, it is difficult to deliver genetic materials,
efficiently and safely despite the hype generated in early* Correspondence: jim.hu@utoronto.ca
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unless otherwise stated.1990s with only few success stories till now [3–5]. One of
the major challenges faced in early gene therapy trials was
the lack of novel delivery vectors with a high efficiency
and easy production in high quality. There has been tre-
mendous research in improving vectors to efficiently ex-
press genes in target cells [6, 7]. Our group has developed
an efficient helper-dependent adenoviral (HD-Ad) vector
to express the human cystic fibrosis transmembrane con-
ductance regulator (CFTR) gene with epithelial cell spe-
cific K18 promoter for cystic fibrosis gene therapy [8].
Another major challenge has been the host immune
responses that eliminate the cells transduced by gene
therapy vectors [9, 10]. In airway gene delivery with
adenoviral (Ad) vectors, apart from the physical barriers
posed by mucus layer and tight junctions, both innate
and adaptive immune responses were found to be a
major problem that makes the transgene expression
transient [10]. The innate immune response is caused bys an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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is largely caused by the leaky expression of viral genes in
addition to the capsid proteins. To reduce the adaptive im-
mune response, a major improvement was made to Ad vec-
tors by creating the HD-Ad vector in which all viral genes
are deleted [11]. We and others have shown that HD-Ad
vectors show long term transgene expression with reduced
immune responses in mice [12, 13]. Because of the deletion
of viral genes, this type of vector has very large gene carry-
ing capacity (37 kb) and can be used to deliver large genes
or multiple genes which cannot be handled by other com-
monly used vectors. We have further developed aeorsoliza-
tion protocol to achieve highly efficient gene delivery to
rabbit lungs using HD-Ad vectors [14]. We have recently
modified our protocol and achieved highly efficient vector
delivery to pig lungs [8].
Since HD-Ad vectors contain the same capsid proteins
as the conventional Ad vectors, they are expected to in-
flict innate immune responses. It is known that immune
cells such as, macrophages [15, 16] and NK cells [17, 18]
are involved in destroying gene therapy vectors or elim-
inating the transduced epithelial cells. Because robust
levels of transgene expression can be maintained for a
long time in rodents [6, 7], but was not achieved in large
animal models, we need to understand how these innate
immune cells affecting gene expression. Our studies with
pig gene delivery show that IFN-γ is induced upon viral
vector delivery [8]. Since NK cells are the major pro-
ducers of IFN-γ in vivo [19], they are likely a barrier to
sustained gene expression in pig airway. Thus, NK cell-
mediated killing of gene transduced cells might be a
major problem unnoticed in past clinical studies.
To understand the problem of immune responses we have
developed an in-vitro co-culture system with human NK cell
line, macrophages and airway epithelial cells. NK cell line,
NK-92 is a human Natural Killer cell line derived from
rapidly progressive non-Hodgkin's lymphoma patient's
peripheral blood mononuclear cells [20]. THP-1 cells are
monocyte cells line grown in suspension, they become
attached once they are differentiated to mature macrophages
in presence Phorbol 12-myristate 13-acetate (PMA) [21].
BEAS-2b, a cell line established from normal human bron-
chial epithelial cells. We used human cell lines in the study
because of the lack of pig cell lines and reagents specific to
pig cells. Eventually, HD-Ad gene therapy has to be tested
in clinical trials; our results with human cell lines will be
useful in designing human applications. To block NK cell,
macrophage and epithelial cell interaction, and NK cell me-
diated killing of gene transduced cells, we targeted NF-κB
and Janus kinase/signal transducers and activators of tran-
scription (JAK-STAT) pathways. These pathways are critical
for producing proinflammatory cytokines (such as, inter-
ferons, IL-6, IL-12, IL-15, IFN-γ) [22, 23]. We used small
molecule blockers ruxolitinib and CAPE to block NF-κband Jak-Stat pathways, respectively. Among the NF-kB in-
hibitors, CAPE [24] and Bay 11–7082 [25] are good candi-
dates because of their potency. We used CAPE because Bay
11–7082 can only be dissolved in DMSO, because DMSO
alone is shown to have influence on cell growth [26]. There
are a quite number of inhibitors available for Jak-Stat path-
ways. We used Ruxolitinib which is a very potent inhibitor
for Jak1 and Jak2 [27] and it is currently used in clinics for
human therapy for myeloproliferative neoplasms [28–30]. In
this paper, we demonstrated that these small molecule in-
hibitors can effectively block the activation of NK cells by
HD-Ad vectors in our co-culture system.
Results
Ruxolitinib and CAPE block activation of macrophages by
HD-Ad vectors
THP-1 cells were cultured in presence of Phorbol 12-
myristate 13-acetate (PMA) for 48 h to differentiate
them into macrophages. Differentiated THP-1 cells were
harvested and cultured in presence of JAK inhibitor
Ruxolitinib (1 μM) and NF-kB inhibiter CAPE (10 μM)
for 24 h. Simultaneously, cohorts of these cells were also
transduced with C4HSU HD-Ad vectors (5000 viral par-
ticles/cell). After 24 h of culturing them in presence of
inhibitors, macrophages were harvested and total RNA
was isolated and analyzed for expression of different cy-
tokines by qRT- PCR analysis. Compared to untrans-
duced macropahges, HD-Ad transduced cells showed
significant increase in the expression of IL-15, IL-12α,
TNF-α and IL-6 (p < 0.001) (Fig. 1). When macrophages
were cultured in presence of ruxolitinib or CAPE, expres-
sion levels of IL-15, IL-12α, TNF-α and IL-6 decreased
significantly compared to HD-Ad transduced cells without
addition of inhibitors. When a combination of both ruxo-
litinib and CAPE were present, expression levels of IL-
15decreased to basal levels as seen in untransduced cells
(Fig. 1). Particularly expression of human IL-6 decreased
very significantly, indicating additive effect of ruxolitinib
and CAPE. Untransduced cells in the presence of inhibi-
tors did not show any effect on cytokine gene expression.
There was no secretion of IFN-γ by macrophages or
significant difference in secretion of IL-1β, IL-8 and
IL-18 between vector-transduced and -untransduced
macrophages (results not shown). Human bronchial
epithelial cells showed an increase in IL-1β, IL-8 secretion
(Additional file 1: Figure S1) when they were transduced
with HD-Ad vectors.
JAK and NF-kB inhibitors block HD-Ad-mediated activation
of NK cells in co-culture with macrophages
NK-92 cells were deprived from IL-2 for 48 h because
NK −92 cells grown in presence of IL-2 are highly acti-
vated and are highly cytotoxic [31, 32]. It is well docu-
mented that IL-2 stimulation of NK cells induces
Fig. 1 Ruxolitinib and CAPE block HD-Ad gene therapy mediated activation of macrophages. THP-1 cells were activated by 5 ng/ml PMA to prepare
mature macrophages. Mature macrophages were harvested and cultured in presence and absence of ruxolitinib or CAPE, and in presence of both the
inhibitors. As depicted in figure one cohort of these culture conditions were transduced with HD-Ad and other cohort was not transduced. After
culturing them for 24 h total RNA was isolated and analysed by qRT- PCR to look for relative expression of different cytokines. Relative expression of
cytokines from one experiment is depicted in the figure. All the data is normalised with GAPDH expression. The significance was calculated by
one-way ANOVA with Tukey’s multiple comparison. *p < 0.05, **p < 0.01, ***p < 0.001
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cytotoxic granules is the dominant mode of cytotoxicity
associated with NK cells. Granzyme B plays an import-
ant role in targeted killing of susceptible cells in both
human and mouse [35–37]. IL-2 deprived NK-92 cells
are co-cultured with activated macrophages (PMA acti-
vated THP-1 cells) in 1:1 ratio. They are co-cultured in
presence and absence of Ruxolitinib and CAPE inhibi-
tors. Simultaneously, a cohort of co-cultured cells were
also transduced with C4HSU HD-Ad vectors (5000 viral
particles/cell). After 24 h culturing, total RNA was iso-
lated from the co-cultured cells and analyzed for expres-
sion of different cytokines by qRT- PCR analysis. Upon
HD-Ad vector transduction, there was a very significant
increase in expression of IL-15,IFN-γ, IL-12α, TNF-α
and IL-6 (p < 0.001) (Fig. 2). IFN-γ is the cytokine se-
creted by NK cells alone in our co-culture system, there
was no expression in macrophages (data not shown).
When vector transduced NK-92 cells alone were cul-
tured in presence and absence of inhibitors, there was
no significant difference in any cytokine secretion (re-
sults are not shown). There was a significant decrease in
INF-γ expression by NK cells cultured in presence ofJAK2 and NF-κB inhibitors. There was an additive effect
on INF-γ secretion in co-cultured cells when both the
inhibitors were used (Fig. 2). Apart from IFN-γ, other
cytokines like IL-15, IL-12α, TNF-α and IL-6 levels were
also significantly decreased in ruxolitinib and CAPE in-
hibitor added cells compared to no-inhibitor. Similar to
macrophage mono culture results there was very signifi-
cant additive effect of inhibitors on human IL-6 expres-
sion in combination inhibitors (Fig. 2). Unlike human
bronchial epithelial cells, NK-92 and THP-1 co-culture
did not show any significant difference in IL-1β, IL-8
and IL-18 secretion upon HD-Ad transduction (Additional
file 1: Figure S1).
NK cell mediated killing of HD-Ad transduced epithelial
cells can be blocked by Ruxolitinib and CAPE
Mature macrophages from activated THP-1 cells are co-
cultured over night with IL-2 deprived NK-92 cells in pres-
ence of the empty HD-Ad vector (C4HSU). Macrophage
activated NK-92 cells were then transferred to overnight
GFP-C4HSU vector (5000 viral particles/cell) transduced
BEAS-2b cells for cytotoxicity assay. Co-cultures were

















































Fig. 2 Ruxolitinib and CAPE block HD-Adv gene therapy mediated activation of NK cells by viral vector activated macrophages. NK-92 cells were
deprived from IL-2 for 48 h and THP-1 cells were activated by 5 ng/ml PMA to prepare mature macrophages. Mature macrophages were harvested
and cultured with NK-92 cells (1:1 ratio) in presence and absence of ruxolitinib or CAPE, and in presence of both the inhibitors. As depicted in figure
two cohort of these culture conditions were transduced with HD-Adv and other cohort was not transduced. After culturing them for 24 h, total RNA
was isolated and analysed by qRT- PCR to look for relative expression of different cytokines. Relative expression of cytokines from one experiment is
depicted in the figure. All the data is normalised with GAPDH expression. The significance was calculated by one-way ANOVA with Tukey’s multiple
comparison. *p < 0.05, **p < 0.01, ***p < 0.001
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co-cultures were incubated for five hours. After incubation
for cytotoxicity, BEAS-2b cells were harvested and stained
for early apoptosis marker allophycocyanin (APC)-conju-
gated Annexin V (Fig. 3) and dead (permeable) cell marker,
7-Aminoactinomycin D (7AAD), (Fig. 4). Stained cells were
analysed on flowcytometer by gating on GFP positive
BEAS-2b cells.
In BEAS-2b monoculture incubated with inhibitors in
combination or alone did not show significant difference
in apoptosis of HD-Ad transduced cells (Fig. 3Ba). There
was a slight reduction of dead cells in combination inhibi-
tor treated BEAS-2b cells (Fig. 4Ba). NK-92 cells activated
by mature THP-1 cells showed significant increase in
apoptosis of HD-Ad transduced BEAS-2b cells, 12.7 % in
co-cultured NK-92 cells compared to 3.24 % in absence of
NK-92 cells (Fig. 3). In parallel, 7AAD stained dead cells
were also significantly more in NK-92 and activated THP-
1 co-cultured BEAS-2b cells, 1.26 % in co-cultured NK-92
cells compared to 0.367 % in absence of NK-92 cells
(Fig. 4). NK-92 mediated killing was effectively blocked by
Ruxolitinib and CAPE, with combination of both the in-
hibitor there was additive effect in inhibiting cytotoxicity
by NK-92 cells. When HD-Ad trasnduced BEAS-2b cellsare co-cultured with THP-1 and NK-92 cells there was sig-
nificant apoptosis in no inhibitor cohort of cells (12.7 %)
and it significantly decreased with CAPE (7.41 %), Ruxoliti-
nib (4.50 %) and there was additive impact with both the
inhibitors (2.89 %) (Fig. 3Bb). In concurrence with
apoptotic cell number, GFP positive dead cells were
also significantly more in no inhibitor cohort of cells
(1.26 %) and their numbers decrease significantly in
CAPE (0.576 %), ruxolitinib (0.46 %) and with both in-
hibitors (0.381) showing additive effect of combination
inhibitors (Fig. 4Bb).
When we used HD-Ad transduced NK-92 cells alone
in cytotoxicity assay, they also showed increased cyto-
toxicity towards HD-Ad transduced BEAS-2b cells.
Apoptosis induced by NK-92 cells on BEAS-2b cells was
significantly high in no inhibitor cohort of cells (9.63 %),
apoptotic cell number significantly decreased with CAPE
(7.71 %), ruxolitinib (5.30 %) and it was 3.87 % with both
the inhibitors (Fig. 3Bc). There was additive effect on
7AAD positive killed BEAS-2b cells when we used com-
bination of both the inhibitors. Killed cells were signifi-
cantly high in no inhibitor cohort of cells (0.879 %)
compared to CAPE (0.619 %), ruxolitinib (0.495 %) and
with both the inhibitors it was 0.204 % (Fig. 4Bc).
Fig. 3 NK cell mediated apoptosis of HD-Ad gene transduced epithelial cells is blocked by Ruxolitinib and CAPE. NK-92 cells were deprived from
IL-2 for 48 h and THP-1 cells were activated by 5 ng/ml PMA to prepare mature macrophages. Mature macrophages were harvested and co-cultured
with NK-92 cells in presence of ruxolitinib or CAPE, and in presence and absence of both the inhibitors for 24 h. NK-92 cells alone were also cultured in
presence of ruxolitinib or CAPE, and in presence and absence of both the inhibitors for 24 h. Both the cohorts of NK-92 and macrophages were
transduced with C4HSU vector. Simultaneously, GFP-C4HSU transduced BEAS-2b cells were also cultured in presence of ruxolitinib or CAPE, and
in presence and absence of both the inhibitors for 24 h. After culturing them for 24 h, NK-92 and macrophages were transferred to respective
BEAS-2b cultures. After incubating those co-cultures for 5 h, BEAS-2b cells were harvested and stained for APC-Annexin V and 7AAD. Samples
were run on flowcytometer and analysed by gating on GFP positive, gene transduced BEAS-2b cells. Percentages of apoptotic gene transduced
BEAS-2b cells are depicted on upper right quadrant of panel (a). Percent apoptotic cells from each row are depicted as separate bar diagram in
panel (b) to better depict significant differences. Results from one experiment is depicted in the figure. The significance was calculated by one-way
ANOVA with Tukey’s multiple comparison. *p < 0.05, **p < 0.01, ***p < 0.001
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Resident alveolar macrophages are abundant in lower re-
spiratory tracts, acting as rapid first line of defense forinvaders. Both macrophages and epithelial cells respond
to viral infection by releasing soluble mediators, helping
in the recruitment of innate and adaptive effector cells.
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Fig. 4 NK cell mediated killing of HD-Ad gene transduced epithelial cells is blocked by Ruxolitinib and CAPE. NK-92 cells were deprived from IL-2
for 48 h and THP-1 cells were activated by 5 ng/ml PMA to prepare mature macrophages. Mature macrophages were harvested and co-cultured
with NK-92 cells in presence of ruxolitinib or CAPE, and in presence and absence of both the inhibitors for 24 h. NK-92 cells alone were also cultured in
presence of ruxolitinib or CAPE, and in presence and absence of both the inhibitors for 24 h. Both the cohorts of NK-92 and macrophages were
transduced with C4HSU vector. Simultaneously, GFP-C4HSU transduced BEAS-2b cells were also cultured in presence of ruxolitinib or CAPE, and
in presence and absence of both the inhibitors for 24 h. After culturing them for 24 h, NK-92 and macrophages were transferred to respective
BEAS-2b cultures. After incubating those co-cultures for 5 h, BEAS-2b cells were harvested and stained for APC-Annexin V and 7AAD. Samples
were run on flowcytometer and analysed by gating on GFP positive, gene transduced BEAS-2b cells. Percentages of 7AAD positive dead gene
transduced BEAS-2b cells are depicted on upper right quadrant of panel (a). Percent dead cells from each row are depicted as separate bar diagram in
panel (b) to better depict significant differences. Results from one experiment is depicted in the figure. The significance was calculated by one-way
ANOVA with Tukey’s multiple comparison. *p < 0.05, **p < 0.01, ***p < 0.001
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[38]. In an established mouse model of respiratory syncyt-
ial virus (RSV) disease, by depleting macrophages through
clodronate liposome mediate depletion of macropahges.
Macrophage depletion specifically affected NK cell re-
cruitment, but not CD4 and CD8 T cells [38]. Up on
viral infection macrophages have been shown to pro-
duce cytokines like IL-15, TNF-α and IL-12 [39–42].
Similarly, our HD-Ad vectors used for gene therapy did
induce secretion of cytokines IL-15, IL-12, TNF-α and
IL-6 when we transduced activated macrophages from
THP-1 cells. Macrophages have also been shown to en-
gulf viral vectors and destroy them through lysosomal
degradation [43]; macrophage suppression may help in
sustained gene expression in lung- gene therapy. In our
study we have used small molecule blockers ruxolitinib
and CAPE to block NF-κB and Jak-Stat pathways, re-
spectively. Both ruxolitinib and CAPE have significant
inhibition on cytokine secretion by macrophages. As both
the inhibitors act on different pathways of activation, there
was additive effect on inhibiting IL-6 and TNF-α secretion
up on using combination of both the inhibitors. However,
these findings are from an in vitro system, we need to
futher confirm them in suitable in vivo system. Recently,
ruxolitinib is shown to inhibit dendritic cell mediate im-
mune response through decreased IL-12 production [30].
NF-κB inhibitor CAPE was shown to have inhibitory effect
on the production of pro-inflammatory cytokines from
LPS-stimulated macrophages by inhibiting cytokine ex-
pression [44].
Macrophages and dendritic cells (DCs) are shown to
regulate the NK cell activity through production of type
I interferons, IL-12 and IL-15 [17, 45–49]. Current un-
derstanding of NK cell development involves the associ-
ation of antigen presenting cells (APCs) for NK cell
activation, because NK cells are not matured in bone
marrow, they come out immature and get activated by
APCs [50]. When NK cells are co-cultured with activated
macrophages, in presence of our HD-Ad, IFN-γ cytokine
expression by NK cells increased significantly. IFN-γ is
only secreted by NK cells in our co-culture, it did not
show any significant variation when NK cells alone were
transduced, indicating the suppressive effect of inhibitors
CAPE and ruxolitinib. IFN-γ expression decreased signifi-
cantly up on incubating them with these inhibitors. There
was additive inhibition on INF-γ secretion when both the
inhibitors were used. In Rag2−/−γc−/− mice transplanted
with human hematopoietic stem cells, membrane bound
IL-15 is shown to effectively stimulate NK cells in to cyto-
toxic effector cells [51]. Although soluble cytokine has
some response membrane bound IL-15 has significant in-
fluence on NK differentiation [51, 52]. To evaluate effect
of contact dependant stimulation in our model, we did co-
culture NK cells and macrophages in transwells with NKcells at the top and activated THP-1 cells at the bottom
well. Twenty-four hrs after incubation both the cells were
harvested separately and looked for expression levels of
cytokines (results are not shown). There was no difference
in expression levels of cytokines, indicating that mem-
brane bound IL-15 alone may not have any significant in-
fluence in our gene delivery system.
We have demonstrated that NK cells activated by cyto-
kines produced by HD-Ad vector activated macrophages
kill HD-Ad vector transduced bronchial epithelial cells.
The apoptotic cell number and number of vector-
transduced epithelial cells killed are significantly reduced
by NF-κB inhibitor CAPE and also by JAK inhibitor rux-
olitinib. Combination of these two inhibitors has an
additive effect on inhibiting NK cell mediate killing of
gene transduced cells. In our previous study we have
seen extensive increase in the IFN-γ at 5 to 7 days,
which is secreted by NK cells, in our HD-Ad mediated
gene therapy of pig lungs. Various viral infection models
have also shown that NK cell response peaks at one week
[53, 54]. Transient inhibition of this NK cell response at
its peak will enhance sustained gene expression.
Conclusions
Based on our study with human cell lines, combination
of CAPE and ruxolitinib will help in protecting gene
transduced air way epithelial cells to prolong transgene
expression by curtailing NK cell mediated deletion of
gene transduced cells. NK cells are also shown to play
an important role in priming and regulation of adaptive
immune responses [55]. As depicted in Fig. 5 effective
inhibition of NK cell response at its peak will also inhibit
HD-Ad capsid mediated adaptive immune response.
Cutting the arm leading to adaptive immune response
will help in the redelivery of HD-Ad vectors for gene
therapy as dampened antigen presentation happens with
suppressed macrophage and NK cell response [56, 57].
Methods
Cell lines and reagents
NK-92 is a human Natural Killer cell line derived from
rapidly progressive non-Hodgkin's lymphoma patient's
peripheral blood mononuclear cells [20]. NK-92 cells were
cultured in minimum essential medium (MEM) alpha
without ribonucleosides and deoxyribonucleosides (Life-
technologies, Burlington, ON, Canada), with 2 mM L-
glutamine (Lifetechnologies, Burlington, ON, Canada),
1.5 g/L sodium bicarbonate (Sigma Aldrich, Missouri,
USA), 0.2 mM inositol (Sigma Aldrich, Missouri, USA),
0.1 mM 2-mercaptoethanol (Sigma Aldrich, Missouri,
USA), 0.02 mM folic acid(Sigma Aldrich, Missouri, USA),
100 U/ml recombinant IL-2 (Peprotech, NJ, USA), 12.5 %
horse serum (Wisent Inc. Quebec, Canada) and 12.5 %

















Fig. 5 Model depicting the interaction of gene transduced bronchial epithelial cells with NK cells and macrophages. Cascade of events leading to
killing of gene transduced bronchial epithelial cells can be broken by transiently inhibiting NK cell activation at its peak response in HD-Ad gene
therapy. Apart from protecting gene transduced cells from NK cell mediated killing, this inhibition will also help in dampening the induction of
adoptive immune response
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tained in RPMI-1640 (Lifetechnologies, Burlington, ON,
Canada) with 10 % FBS and 0.05 mM 2-mercaptoethanol.
THP-1 cells were differentiated to mature macrophages in
presence of 5 ng/ml Phorbol 12-myristate 13-acetate
(PMA) for 48 h. PMA was obtained from Sigma Aldrich,
Missouri, USA. BEAS-2b, a cell line established from nor-
mal human bronchial epithelial cells, was obtained from
the American Type Culture Collection (ATCC). These cells
were maintained in Dulbecco's Modified Eagle's Medium
(DMEM) (Lifetechnologies, Burlington, ON, Canada) with
10 % FBS. Ruxolitinib, a Janus kinase inhibitor was ob-
tained from LC laboratories Woburn, MA, USA. Caffeic
acid phenethyl ester (CAPE) was obtained from Tocris bio-
science, Bristol, United Kingdom.
Helper dependant Adenoviral vector production
Design and production of the HD-Ad vectors expressing
GFP and empty/pC4HSU vectors used in this study were
described previously [12, 59]. Briefly a GFP gene expres-
sion cassette was cloned into the pC4HSU vector which
was linearized with a restriction enzyme, Pme I, for viral
production. HD-Ad vectors were produced and purified
by CsCl gradient centrifugation.
Quantitative Real time PCR
For mRNA expression analysis, total RNA was isolated
form cells by using the Qiagen RNAeasy kit (Qiagen,
Mississauga, Ontario, Canada) according to the manu-
facturer's instructions, followed by DNase digestion. One
μg of total RNA obtained was reverse transcribed using
random hexamers and SuperScript II reverse transcriptase((Invitrogen, Carlsbad, CA, USA) following the manu-
facturer's protocol. Ten ng of cDNA were then used as
template for real-time PCR using SYBR Green in ABI
prism 7000 (Life Technologies Inc., Burlington, ON,
Canada). The primers used for detecting different cytokine
levels are as follows: hIL-15 Forward-CAGAAGCCAAC
TGGGTGAATG and Reverse- GGGTGAACATCACTTT
CCGTATA, hIL-12α Forward-CGTCAGCAACATGCTC
CAGAA and Reverse- GGCAACTCTCATTCTTGGTTA
ATTC, hIFN-γ F:orward-GGGTTCTCTTGGCTGTTAC
TG and Reverse- CTGTCACTCTCCTCTTTCCAATTC,




Flowcytometric apoptosis and cytotoxicity assay
NK-92 cells were cultured in complete NK-92 growth
medium without IL-2 supplement for 48 h, to deprive
them from IL-2. Simultaneously, THP-1 cells were dif-
ferentiated into mature macrophages in presence of
5 ng/ml PMA for 48 h. After 48 h mature macrophages
attached to culture plates were harvested by using Accutase
(Sigma-Aldrich Canada Co. Oakville, Ontario Canada) and
co-cultured with IL-2 deprived NK-92 cells in 1:1 concen-
tration, in presence and absence of different inhibitors and
C4HSU vector (5000 viral particles/cell) as depicted in fig-
ures, for one day. Mono cultures of IL-2 deprived NK-92
cells were also incubated with and without inhibitors, and
C4HSU vector (5000 viral particles/cell) as depicted in fig-
ures, for one day. Simultaneously, one day after starting the
IL-2 deprival for NK-92 and THP-1 differentiation to
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sue culture dishes at 2X105 cells per plate. Next day, media
in those plates were replaced with or without GFP express-
ing vector (5000 viral particles/cell) as depicted in figure, in
serum free RPMI-1640 for vector transduction. After two
hours the media in all BEAS-2b plates were replaced with
RPMI-1640 with 10 % FCS and cultured for one day. Later,
co-cultured NK-92 and macrophages, and also mono cul-
tured NK-92 were added to respective BEAS-2b plates as
depicted in figures, in 5:1:1 (BEAS-2b: NK-92: THP-1) ra-
tio. (Note: when we transfer co-cultured NK-92 and macro-
phages, though we mix and transfer those cells to BEAS-2b
plates we are not transferring attached macrophages). Five
hours after co-culturing these cells together, BEAS-2b cells
were harvested using Trypsin EDTA (Lifetechnologies,
Burlington, ON, Canada). Harvested cells were washed
with PBS, and stained with Annexin V-APC (eBioscience
Inc., San Diego, CA, USA) and 7AAD (eBioscience Inc.,
San Diego, CA, USA) for 30 min, in Annexin staining buf-
fer (eBioscience Inc.) as per manufacturers protocol. After
30 min 300 μl of Annexin binding buffer was added and
samples were analyzed on BD LSR-II flowcytometer (BD
Biosciences, Mississauga, ON, Canada). GFP positive vector
transduced BEAS-2b cells were gated and further analysed
for apoptotic Annexin V and killed 7AAD positive popula-
tion of GFP transduced BEAS-2b cells.
Statistical analysis
All experiments were performed at least for 3 times,
with representative experiments shown in figures. To
test for statistical significance one-way ANOVA was
done with Tukey's post hoc test, and Mann–Whitney
test, using Prism 5 software.
Supplementary information is available at Cell and
Biosciences website.
Additional file
Additional file 1: Figure S1. HD-Adv transduced bronchial epithelial
cells produce pro-inflamatory cytokines. One cohort of BEAS-2b cells were
transduced with HD-Adv and other cohort was not transduced and cultured
for 24 h. After culturing them for 24 h total RNA was isolated and analysed
by qPCR to look for relative expression of different cytokines. Relative
expression of cytokines from one experiment is depicted in the figure.
The significance was calculated by Mann–Whitney U test.
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